Epizyme (EPZM) 10-K2018 FY Annual report

Filed: 26 Feb 19, 6:46am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abiraterone, acetyl, acetyltransferase, AE, Agarwal, aimed, Anesthesiology, appetite, argued, ASPHO, AVEO, aware, Baltimore, basket, belief, benchmarking, BI, blueprint, Boehringer, boost, bribery, built, Bulletin, catalyze, catch, child, Circuit, compassionate, constraint, contextualize, correlated, corridor, counterparty, Covidien, CRPC, cure, cybersecurity, dashboard, DCR, defaulting, denial, deployment, duvelisib, endorsement, engineering, entertainment, enzalutamide, Ernst, ESMO, excessive, expedient, expert, exploit, fall, Fifty, flexibility, gag, gaming, GDPR, GmbH, GMP, HAT, helicase, HHS, highlight, hope, inadvertent, indefinitely, India, Ingelheim, jointly, JSC, judge, Karnataka, licensee, lifted, linked, LLP, lodge, Mahadevappa, malware, Master, membership, Merrick, modest, niraparib, noncurrent, Nonemployee, notification, opt, opted, ORR, outset, oversaw, owner, Parliament, PARP, permission, phishing, placebo, power, PRMT, proactively, Rampure, ransomware, rationale, reclassification, reconsented, remedy, restraining, resume, resuming, resumption, Revlimid, ROW, SAB, SCLC, Shefali, social, SoLO, sophistication, SQZ, step, STS, subgroup, sublease, subtenant, suit, supervisory, synergistic, Tesaro, thereon, transferase, transmit, transmitted, transportation, true, UK, unaddressed, undergoing, unfairly, unqualified, unreasonable, unsatisfied, valemetostat, vi, whichever, worse, ZEJULA

Removed: adjusting, adversarial, Alimta, allogeneic, alteration, API, attribution, catalytic, childhood, chromosomal, chromosome, cisplatin, complying, condensed, conversion, donor, dozen, exploring, expressing, functional, golden, integrated, intensive, intervention, intravenously, irrevocably, Jumpstart, lineage, lining, location, matched, methylation, MLL, myeloblastic, neutropenia, nonbinding, operation, parachute, partnered, pemetrexed, professor, reacquire, readily, reallocated, recruited, regulator, reliable, remained, remission, remodeling, repression, reproducible, resell, Room, rotation, signaling, Singer, steroid, substrate, subtype, subunit, synthetic, transcription, translocation, transplant, Treasurer, trimethylation, unusual, vendor, Washington, week

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EPZM transcripts

EPZM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Annual Report on Form 10-K of Epizyme, Inc. (the “Company”) for the year ended December 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 26, 2019

/s/ Robert B. Bazemore

Robert B. Bazemore

President and Chief Executive Officer

/s/ Matthew E. Ros

Matthew E. Ros

Chief Strategy and Business Officer